Multi-Dimensional Health Assessment Questionnaire in China: Reliability, Validity and Clinical Value in Patients with Rheumatoid Arthritis

Song, Yang; Zhu, Lian; Wang, Suli; Leng, Lin; Bucala, Richard; Lu, Liangjing

doi:10.1371/journal.pone.0097952

Cited by 6 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10 A study by Song Y et al, on RA has shown that clinical disease activity as assessed by Routine Assessment of Patient Index Data (RAPID) improved quality of life by improving physical function, pain and global health status. 11 In the present study the RAPID-3 score has been found to be decreased at 16 weeks by -1.02 (from 3.67±0.06 at baseline to 2.65±0.09 at 16 weeks), 1.66 (from 3.79±0.09 at baseline to 2.13±0.15 at 16 weeks) in group 1, group 2 respectively. In the study by Pincus T et al, RAPID-3 score was found to be effective as a guide to assess continuous quality of life.…”

Section: Discussionsupporting

confidence: 55%

Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

Kaur

Dutta

Singh

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Rheumatoid arthritis (RA) a chronic autoimmune inflammatory disease and Methotrexate being widely used as monotherapy and in combination for the treatment of RA. Combination therapy provides additional or even more potentiating effects, therefore have been widely used. This study is aimed at comparing the efficacy and safety of Methotrexate either alone or in combination.Methods: This study was conducted for one year from 1st January to 31st December 2015. 52 patients diagnosed with RA were included in this study and were divided in two groups, Group-1 (n=29) patients received methotrexate (MTX) 7.5-15mg/week and Group-2 (n=23) patients received methotrexate 7.5mg once a week + Hydroxychloroquine (HCQ) 200mg twice daily. The patients were followed up for a period of 16 weeks. Statistical analysis was done by using graph pad insta and p value of <0.05 was considered significant.Results: A total of 52 patients were included in the study. The mean age of patients was 50.53±14.81 years. 43 (82.69%) patients were females and 9 (17.30%) were males. 23 (44.23%) patients had positive family history of the disease. The Rheumatoid factor was positive in 42 (80.70%) and anti-CCP was raised in 50 (96.15%) patients. The RAPID-3 and DAS-28 scores on intragroup comparison was highly significant (p <0.0001) and the intergroup comparison was significant (p <0.01) between baseline and 16 weeks in both the groups. The improvement in inflammatory marker CRP was highly significant on intragroup (p <0.0001) and intergroup (p<0.001) comparison between baseline and 16 weeks in both the groups. The mean changes in Vitamin-D3 between baseline and at 16 weeks were insignificant (p >0.05) in both the groups. Total of Adverse drug reactions reported were 42 (50.60%) in group-1 and 41 (49.40%) in group-2.Conclusions: The combination therapy was found to be more efficacious than MTX monotherapy in improving symptoms and quality of life. The adverse drug reactions were mild, more in combination therapy and none of the patients required withdrawal of treatment.

show abstract

Section: Discussionsupporting

confidence: 55%

Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

Kaur

Dutta

Singh

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…In a previous study, Corniola et al reported that there were no associations between disc degeneration and pain intensity, the Oswestry Disability Index (ODI) score, or the EQ-5D score in subjects with degenerative disc disease of the lumbar spine. 18 ) Moreover, they did not find any association between disc degeneration and functional performance. Another study reported that there was no correlation between pain intensity and Modic changes in patients with LBP who were indicated for surgery.…”

Section: Discussionmentioning

confidence: 91%

Associations between Paraspinal Muscle Morphology, Disc Degeneration, and Clinical Features in Patients with Lumbar Spinal Stenosis

Miki

Fujita²,

Takashima

et al. 2020

PRM

View full text Add to dashboard Cite

Objective: The purpose of this study was to examine the relationships between intervertebral disc degeneration in the lumbar spine, paraspinal muscle morphology, and clinical features in patients with lumbar spinal stenosis (LSS). Methods: A total of 52 patients with LSS participated in this study. Magnetic resonance imaging was used to assess intervertebral disc degeneration at L4/5 and to measure the standardized cross-sectional areas (SCSAs) of the multifidus and erector spinae muscles. The intensity of low back pain (LBP) and lower limb pain, the level of disability, and the quality of life (QoL) were evaluated using patient-reported outcome measures. The associations between the image findings and clinical features, including the disability score, the pain score for low back pain, and the QoL score, were calculated using Spearman’s rank correlation coefficient. Results: No associations were found between disc degeneration and clinical features. However, disc degeneration and the SCSA of the multifidus muscle ( r =−0.38, P <0.01) and of the erector spinae muscle ( r =−0.29, P=0.04) were significantly associated. Analysis of the associations between muscle morphology and clinical features found that the SCSA of the multifidus muscle was associated with LBP ( r =0.31, P=0.03). Conclusions: These results suggest that there is some correlation between atrophy of the multifidus and pain intensity. Consequently, focusing on the CSA of the multifidus muscle may help to clarify the causes of LBP in patients with LSS. However, because of the cross-sectional nature of this study, causal relationships could not be determined and further research is needed.

show abstract

“…For both Chinese medical practitioners and RA patients, MDHAQ-C proved to be a reliable and informative measurement for HRQoL in demanding clinical settings. 39 …”

Section: Perspectives On Patient’s Quality Of Lifementioning

confidence: 99%

Management of rheumatoid arthritis in People's Republic of China – focus on tocilizumab and patient considerations

Wang¹,

Mu²,

Xu³

2015

IJGM

View full text Add to dashboard Cite

The prevalence of rheumatoid arthritis (RA) is 0.19%–0.41% in Chinese population. RA exerts profound influence on health-related quality of life (HRQoL), which imposed huge burdens on patients physically, mentally, and economically. As a developing country, People’s Republic of China faces enormous challenges in management of RA. Conventional-synthesized disease-modifying antirheumatic drugs (csDMARDs) remain the most selective therapeutic options for RA in People’s Republic of China owing to their affordable price and fair efficacy as well as tolerability. Unfortunately, there are substantial RA patients who are poor responders to csDMARDs, even to subsequently combined therapy with tumor necrosis factor antagonist (anti-TNF). Tocilizumab (TCZ) has been approved as a subsequent-line biological agent in patients with moderate-to-severe RA worldwide including People’s Republic of China. TCZ is the first biological agent approved for the treatment of RA inhibiting interlukin-6 (IL-6) by blocking both membrane-bound and soluble IL-6 receptors. Open-label studies in real-life practice and strictly controlled clinical trials demonstrated its high efficacy and safety profile in treatment of patients with RA who have inadequate responses to csDMARDs and anti-TNF. HRQoL of RA patients was improved in various measurements. TCZ was associated with 1.2 times the risk of adverse events, such as infections, dyslipidemia, and hepatic transaminases elevation, compared with pooled placebo. A relatively long half-life allowing for monthly intravenous administration and a newly developed subcutaneous injection make TCZ more acceptable. However, data are not enough so far comparing TCZ to anti-TNF. Lack of evidence in Chinese patients and high cost of TCZ limit its prescription in People’s Republic of China being a developing country. Further clinical trials and post-marketing surveillance may offer a comprehensive assessment of patient satisfaction and acceptability, which may help us define the optimal role for TCZ in therapeutic strategy.

show abstract

Multi-Dimensional Health Assessment Questionnaire in China: Reliability, Validity and Clinical Value in Patients with Rheumatoid Arthritis

Cited by 6 publications

References 30 publications

Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

Associations between Paraspinal Muscle Morphology, Disc Degeneration, and Clinical Features in Patients with Lumbar Spinal Stenosis

Management of rheumatoid arthritis in People's Republic of China – focus on tocilizumab and patient considerations

Contact Info

Product

Resources

About

Multi-Dimensional Health Assessment Questionnaire in China: Reliability, Validity and Clinical Value in Patients with Rheumatoid Arthritis

Cited by 6 publications

References 30 publications

Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

Comparative evaluation of efficacy and safety of methotrexate either alone or in combination with hydroxychloroquine in patients suffering from rheumatoid arthritis

Associations between Paraspinal Muscle Morphology, Disc Degeneration, and Clinical Features in Patients with Lumbar Spinal Stenosis

Management of rheumatoid arthritis in People&#39;s Republic of China &ndash; focus on tocilizumab and patient considerations

Contact Info

Product

Resources

About

Management of rheumatoid arthritis in People's Republic of China – focus on tocilizumab and patient considerations